1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters

Showing 1,267 results.

CLL - 787

Micro-Dosed Obinutuzumab: A Novel Debulking Strategy in a Rare Case of Leukostasis From Chronic Lymphocytic Leukemia

Ahmed Qaedi

Poster Presenter: Ahmed Qaedi

Thumbnail for Risk Stratification and Overall Survival in Patients With Primary Myelofibrosis in Armenia: Real-World Data From a 10-Year Cohort

MPN - 788

Risk Stratification and Overall Survival in Patients With Primary Myelofibrosis in Armenia: Real-World Data From a 10-Year Cohort

Levon Evoyan

Poster Presenter: Levon Evoyan

Thumbnail for First-Line Treatment Patterns and Outcomes in Older Patients With Hodgkin Lymphoma in a Resource-Limited Setting: A Real-World Retrospective Single-Center Study

HL - 789

First-Line Treatment Patterns and Outcomes in Older Patients With Hodgkin Lymphoma in a Resource-Limited Setting: A Real-World Retrospective Single-Center Study

Vijaya Moorthy Giri Raja Pandian

Poster Presenter: Vijaya Moorthy Giri Raja Pandian

Thumbnail for Risk-Stratified Survival and Treatment Patterns in MDS: A Nationwide Analysis from the Spanish Group of Myelodysplastic Syndromes (GESMD)

MDS - 790

Risk-Stratified Survival and Treatment Patterns in MDS: A Nationwide Analysis from the Spanish Group of Myelodysplastic Syndromes (GESMD)

Ra?l Azibeiro Melchor

Poster Presenter: Ra?l Azibeiro Melchor

AML - 791

Is MRD Negativity a Valid Surrogate for Overall Survival in RandomizedTrials of Acute Myeloid Leukemia?

Vivian Reis Ferrarez

Poster Presenter: Vivian Reis Ferrarez

AML - 792

Treatment Patterns and Outcomes with Olutasidenib After Venetoclax in IDH1-Mutated AML Using Real-World Data from Chart Review

Amber Thomasson

Poster Presenter: Amber Thomasson

$Thumbnail for Early Resolution of Talquetamab Oral Side Effects in Relapsed/Refractory Multiple Myeloma (RRMM): Updated Waterless Empirical Taste Test (WETT) and Patient Reported Outcomes (PRO) Data From TALisman$

MM - 793

Early Resolution of Talquetamab Oral Side Effects in Relapsed/Refractory Multiple Myeloma (RRMM): Updated Waterless Empirical Taste Test (WETT) and Patient Reported Outcomes (PRO) Data From TALisman

Nolan Ngo

Poster Presenter: Nolan Ngo

Thumbnail for Sustained Long-Term Control of Terminal Complement Activity With Ravulizumab or Danicopan Add-On to Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria

MDS - 794

Sustained Long-Term Control of Terminal Complement Activity With Ravulizumab or Danicopan Add-On to Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria

Pennie Moore

Poster Presenter: Pennie Moore

$Thumbnail for Treatment-Limiting On-Target Toxicity With Talquetamab/GPRC5D-Directed Therapy in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis$

MM - 795

Treatment-Limiting On-Target Toxicity With Talquetamab/GPRC5D-Directed Therapy in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis

Ayse Gul Korkmaz

Poster Presenter: Ayse Gul Korkmaz